IMUC (IMUC) Stock Price & Analysis
IMUC (IMUC) rose 0.00% to USD 0.25 as of June 10, 2026 at 04:06 UTC, according to Nexqual real-time market data.
IMUC last closed at USD 0.25; the session ranged USD 0.25–0.27 on volume of 2,600 shares. Market capitalization is $31.63M, with a 52-week range of USD 0.04–0.34 (PNK). Source: Nexqual, June 10, 2026 at 04:06 UTC.
Key Statistics (as of June 10, 2026 at 04:06 UTC)
| Price | USD 0.25 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0.25 |
| Open | USD 0.27 |
| Day Range | USD 0.25 – 0.27 |
| 52-Week Range | USD 0.04 – 0.34 |
| Volume | 2,600 shares |
| Market Cap | $31.63M |
| Exchange | PNK |
Technical Analysis (IMUC)
Nexqual's technical model rates IMUC "BUY" based on 5 bullish and 2 bearish signals across 123 daily candles, as of June 10, 2026 at 04:06 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 73.63 (overbought) |
| vs SMA50 | Above (USD 0.13) |
| MACD | 0.02 (positive) |
Analyst Ratings (IMUC)
Wall Street analysts rate IMUC "None", per Nexqual as of June 10, 2026 at 04:06 UTC.
| Consensus Rating | None |
|---|
Earnings (IMUC)
Source: Nexqual, June 10, 2026 at 04:06 UTC.
Financials & Fundamentals (IMUC)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.97 |
| Total Cash | $551,176 |
| Total Debt | $3.05M |
| Free Cash Flow | $-1.99M |
Source: Nexqual, June 10, 2026 at 04:06 UTC.
Financial Health Score (IMUC)
Nexqual rates IMUC's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 04:06 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Mixed — $551K cash vs $3M debt |
| Cash Flow | Weak — Operating cash flow -$3M |
| Efficiency | Mixed — No data |
Ownership (IMUC)
| Insider Ownership | +94.97% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 126.50M |
| Float | 5.70M |
| Short % of Float | +3.96% |
Source: Nexqual, June 10, 2026 at 04:06 UTC.
Leadership (IMUC)
IMUC is led by Irach B. Taraporewala B.S., M.S. (age 69), CEO, President & Director, per Nexqual as of June 10, 2026 at 04:06 UTC.
| CEO, President & Director | Irach B. Taraporewala B.S., M.S. (age 69) |
|---|---|
| CFO & Treasurer | Wayne I. Danson (age 71) |
| Founder, Chairman & COO | Eli Goldberger (age 34) |
| Co-Founder, Chief Scientific Officer & Medical Director | Shalom Z. Hirschman (age 89) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NWBO | Northwest Biotherapeutics, Inc. | USD 0.19 | ▼ 4% |
| BGMSP | Bio Green Med Solution Inc. | USD 0.7 | ▲ 0.86% |
| ANTH | ANTHERA PHARMACEUTICALS INC | USD 0 | ▲ 0% |
| CLDX | Celldex Therapeutics, Inc. | USD 29.6 | ▲ 3.42% |
| CSCIF | COSCIENS Biopharma Inc | USD 2.05 | ▲ 12.64% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 04:06 UTC. This page is informational and not investment advice.